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Abstract  
It has taken me almost 19 years and observing/enduring/ignoring 20 seasons of dengue fever in our country’s 
capital, Delhi to finally say “Enough is enough”. How many more precious lives dengue will consume before 
infrastructure resolves to fight back and eradicate dengue. Why the development of vaccine has been difficult for 
this mosquito borne disease. The good news is that the WHO has promising data accumulation in favor of live 
attenuated recombinant tetravalent dengue vaccine titled CYD-TDV that has taken up the arduous challenge to 
counter all four serotypes of dengue virus. Hopefully, by April 2016, the WHO may have their recommendations 
(if any) about how and when to use CYD-TDV. Subsequently, the ball will be in the court of dengue-endemic 
nations’ regulatory authorities to take on the implementations of the WHO recommendations. Herein will lay the 
prerogative of dengue-endemic nations’ physician-entrepreneurs/pharmaceutical-entrepreneurs in the Third 
World (my world) to take it upon them to ensure that although they have been slow to catch up (already 20 
seasons have flown past), they should not miss the train now once the WHO publishes its recommendations in 
near future so that hopefully, the next season sees the dawn of hope and shifting of gears from economy -draining 
sluggish anti-dengue campaign to economy-driving future eradicate-dengue campaign initiating from the dengue-
endemic nations across the world, including India. 
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Introduction 
I remember it like yesterday when I was reading 
Park’s Textbook of Preventive and Social Medicine 
(14th Edition) (1) for my Final Professional Part-I 
examinations (we used to abbreviate the subject as 
SPM and the examination as Mini-Prof) during the 
fall of 1996-97. To us, dengue fever was a foreign 
disease (with a limited mention in our SPM textbook 
and I am pretty sure it was summarized in one page 
or so), and our focus was to excel know-how about 
our disease, malaria, to score good in our Mini-Prof. 
As the examinations drew nearer, we started 
cramming about dengue too because that year, an 
“out-of-blue” epidemic of dengue happened in Delhi 
area and it was clearer to us that we will be tested 
about comparative differences of dengue vs. malaria 
in our written examination and/or viva-voce of SPM. 
The testing in new, current and rare diseases has 
often been the norm to motivate superlative medical 
students to score higher grades than the rest. I do 
not remember whether and where our knowledge 
about dengue fever was actually tested but October 
1996’s outbreak of dengue in Delhi (per the WHO 
Weekly Epidemiological Record (2) quoting The 
National Institute of Communicable Diseases, 
claiming 297 lives among 7427 cases with 4% 
mortality by October 1996 although later sources 
INDIAN JOURNAL OF COMMUNITY HEALTH / VOL 27 / ISSUE NO 04 / OCT – DEC 2015                                       [Dengue Preventive Strategies…] | Gupta D et al 
510 
have reported higher numbers for the completed 
season 1996-1997) led Park’s Textbook of Preventive 
and Social Medicine (15th Edition) published in 
September 1997 (3) to broaden the coverage to two+ 
pages about dengue fever. By the time my sister read 
about dengue in the following years, SPM textbook 
(3) reinforced that first recorded outbreak of dengue 
fever (1812), its first serological survey (1952), its 
first double peak epidemic (1963-64), its recurring 
outbreaks (1967 & 1970) and confirmation of 
dengue’s endemicity (1982) with exorbitant 
case/death numbers in 1996 in Delhi cried out loud 
and clear that dengue could NO LONGER be a foreign 
disease. 
As time passed by, year after year, the only time we 
remembered about dengue were when rains started 
pouring and it was time to ensure mosquito nets, 
mosquito repellants and full sleeves clothes not only 
during the nights (for protection against malaria) but 
also during the daytimes (for protection against 
dengue). These measures became more labor-
intensive and stress-inducing when the time came to 
move for further studies and future job in United 
States of America because visits back home during 
scheduled vacations often required the 
consideration for gravitas of prevalent dengue 
epidemic during the current season/year. During 
these times, my only and very limited contribution to 
the awareness about dengue was when last year, I 
guided in preparation and copy-editing of the 
manuscript titled POST-MONSOON SEASON 
SURVEILLANCE A MUST FOR CURTAILING ANNUAL 
DENGUE EPIDEMIC IN RURAL INDIA (4). However, it 
has taken me almost 19 years and 
observing/enduring/ignoring 20 seasons of dengue 
fever in our country’s capital, Delhi to finally say 
“Enough is enough”. Why this annual ritual for 
dengue prevention and management for few months 
and then to be forgotten for the rest of the year. How 
many more precious lives dengue will consume 
before infrastructure resolves to fight back and 
eradicate dengue. Why the development of vaccine 
has been difficult for this mosquito borne disease. 
Even the noble research processes and unique 
techniques used by Dr. Brian D. Foy and his team (5-
8) over the last decade or so are still ongoing that 
focus on making the human blood potentially lethally 
toxic to the mosquitoes feeding on them so that 
vector burden of the mosquito borne diseases can be 
reduced or exterminated. My presumption is that 
this may or may not lead to mosquito populations 
becoming potentially averse to feeding on humans 
and consequently start savoring non-human blood. 
My own personal unique perspective is that whether 
there can be scenario in future when mosquitoes 
ingesting on treated/vaccinated human blood 
become sterile/infertile (decreased to abolished egg 
production like with abortifacients) and subsequent 
environmental adaptation for survival in current 
mosquito populations may cause genetic changes (if 
that phenomenon is part of any living systems 
evolutionary learning to prevent loss-of-
reproduction-based-extinctions) in future mosquito 
generations so they avoid (forget) feeding on 
“abortifacient” human blood. 
In the real world, the good news is that the WHO 
under its Initiative for Vaccine Research (part of 
broader Dengue Vaccine Initiative) (9) has promising 
data accumulation in favor of live attenuated 
recombinant tetravalent dengue vaccine titled CYD-
TDV that has taken up the arduous challenge to 
counter all four serotypes of dengue virus. Hopefully, 
by April 2016, the WHO Strategic Advisory Group of 
Experts on Immunization will have reviewed data, 
discussed pros-cons and accordingly might have 
advised the WHO their recommendations (if any) 
about how and when to use CYD-TDV. Subsequently, 
the ball will be in the court of dengue-endemic 
nations’ regulatory authorities to take on the 
implementations of the WHO recommendations. 
Herein will lay the prerogative of dengue-endemic 
nations’ physician-entrepreneurs/pharmaceutical-
entrepreneurs to take it upon them to ensure that 
the economic value deemed to the lives saved/sick-
days avoided per year and economic value deemed 
to the vaccines required per year to cover the whole 
population at-risk will further drive pharmaceutical-
based national economies to greater heights. To 
analogously quote reports/data from influenza (flu) 
economics, with an estimated flu-related lost lives 
between 3K to 49K over a period of 30 years (1976-
2006) (10) and an estimated total economic burden 
of 87.1 billion USD annually (C.I., 47.2 billion USD, 
149.5 billion USD) due to flu seasons (base year 
burden estimated in 2003) (11), flu vaccination is an 
annual “must” in United States of America per 
Centers for Disease Control and Prevention leading 
to 1.6 billion USD worth flu-vaccine sales in 2011 that 
is forecasted to increase to 2.2 billion USD annually 
by 2018 (12). Learning from the historical and 
current examples of health economics of seasonal 
influenza and economics of flu vaccinations (13-18) 
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can inculcate rapid development of dengue vaccine 
as a great economic incentive and driving force for 
the physician-entrepreneurs/pharmaceutical-
entrepreneurs so as to make or break the case of 
universal dengue vaccination for population at-risk 
in dengue-endemic nations. 
In summary, although physician-
entrepreneurs/pharmaceutical-entrepreneurs in the 
Third World (my world) have been slow to catch up 
(already 20 seasons have flown past), they should 
not miss the train now once the WHO publishes its 
recommendations in near future so that hopefully, 
the next season sees the dawn of hope and shifting 
of gears from economy-draining sluggish anti-
dengue campaign to economy-driving future 
eradicate-dengue campaign initiating from the 
dengue-endemic nations across the world, including 
India. 
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